	US 11,897,926 B2
	GIPR-agonist compounds
Jorge Alsina-Fernandez, Indianapolis, IN (US); Andrea Renee Geiser, Greenwood, IN (US); Lili Guo, Carmel, IN (US); Samantha Grace Lyons Keyser, Carmel, IN (US); John Lee, Carmel, IN (US); Hongchang Qu, Carmel, IN (US); and William Christopher Roell, Avon, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Jan. 11, 2022, as Appl. No. 17/573,317.
Application 17/573,317 is a continuation of application No. 16/941,990, filed on Jul. 29, 2020, granted, now 11,254,721.
Claims priority of provisional application 62/881,685, filed on Aug. 1, 2019.
Prior Publication US 2022/0127315 A1, Apr. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/16 (2006.01); C07K 14/47 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/4703 (2013.01) [A61K 38/00 (2013.01)]

4 Claims

1. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is SEQ ID NO:7.